On February 11, 2026, Galderma announced the launch of Restylane Defyne and Restylane Refyne, the first OBT-based hyaluronic acid injectables authorized in Japan. This expands Galderma’s Restylane portfolio in Japan to four products and underscores the company’s growth in the Asia Pacific region.
Restylane Defyne and Refyne are designed for injection into the mid-to-deep dermis for the correction of moderate to severe facial wrinkles and folds. Further, the company’s proprietary OBT is designed to move in harmony with facial expressions while maintaining shape and lift.
“The introduction of OBT technology to Japan is a significant milestone not only for clinicians but for the region’s aesthetic landscape as a whole,” said Dr. Stephane Lam, plastic surgeon at Central Health Medical Practice in Hong Kong. “By combining the power of both NASHA and OBT with the Restylane portfolio in Japan, physicians can tailor treatments more precisely than ever before. This broader set of tools supports natural-looking, expressive outcomes and aligns Japan with international best practices.”
According to the company’s press release, Restylane Refyne offers a smooth, flexible gel and is ideal for delicate, highly expressive areas. Restylane Defyne provides support for areas such as the jawline and deeper facial folds. The approvals of these products were based on two double-blinded, randomized, active-controlled phase III studies. Both products met the studies’ endpoints and demonstrated a clinically meaningful improvement in wrinkle severity for up to 12 months.”
“The approval of Restylane Refyne and Defyne – the first OBT HA injectables ever authorized in Japan – is a landmark movement for Galderma in the region,” said Hon Keong Choo, head of the JPAC region at Galderma. “A decade after NASHA’s introduction to this market, we are proud to now offer a fully rounded Restylane portfolio that gives healthcare professionals even more precision and flexibility to meet the needs of their patients. Japan is an important growth engine for our business, and this milestone underscores our long-term commitment to bringing world-leading aesthetic technologies to the region.”
